Regulation - North America

Filter

Current filters:

North America

Popular Filters

1030 to 1054 of 3305 results

Novartis' Lucentis first drug approved in EU for myopic choroidal neovascularization

05-07-2013

The European Commission has granted Swiss drug major Novartis (NOVN: VX) a new indication for Lucentis…

EuropeLucentisNovartisOphthalmicsPharmaceuticalRegulation

Indian pharma threatened by trend of shifting R&D operations overseas: survey

04-07-2013

Red tape is putting India's multi-billion dollar worth pharmaceutical industry at risk, with most of…

Asia-PacificGenericsMarkets & MarketingPharmaceuticalRegulationResearch

Orexo gets US FDA approval for opioid dependence drug Zubsolv

04-07-2013

Swedish drug developer Orexo (STO: ORX) today (July 4) received approval from the US Food and Drug Administration…

Orexo ABPharmaceuticalReckitt BenckiserRegulationSuboxoneZubsolv

Next generation sequencing market expected to grow to $2.7 billion by 2017

04-07-2013

The next generation sequencing (NGS) market has been forecast to increase at a compound annual growth…

BiotechnologyEuropeGeneticsIlluminaMarkets & MarketingNorth America

Impax Labs confirms patent challenge to Pfizer/UCB's Toviaz

04-07-2013

US specialty drugmaker Impax Laboratories (Nasdaq: IPXL) yesterday confirmed that it has initiated a…

Gastro-intestinalsGenericsImpax LaboratoriesNorth AmericaPatentsPfizerToviazUCB

Roche granted FDA Priority Review for obinutuzumab in the treatment of chronic lymphocytic leukemia

03-07-2013

Swiss drug major Roche (ROG: SIX) has announced today (July 3) that the US Food and Drug Administration…

obinutuzumabOncologypertuzumabPharmaceuticalRegulationRoche

EFPIA releases code on financial relations with health care professionals

03-07-2013

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has released its disclosure…

BiotechnologyEuropeFinancialMarkets & MarketingPharmaceuticalRegulation

EU falsified medicines directive: imported active substances need written confirmation to guarantee GMP standards

03-07-2013

From July 2, 2013, all active substances manufactured outside of the European Union and imported into…

EuropeGenericsGlobalPharmaceuticalProductionRegulation

Avanir in up to $110 million deal with OptiNose for migraine product

03-07-2013

US drugmaker Avanir Pharmaceuticals (Nasdaq: AVNR) has entered into an exclusive North American license…

Avanir PharmaceuticalsLicensingNeurologicalNorth AmericaOptiNosePharmaceuticalsumatriptan

US FDA backs news indications for Latuda; grants Priority Review for Perjeta

02-07-2013

Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

BiotechnologyDainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaOncologyPerjetaPharmaceuticalRegulationRocheSunovion

US FDA delays Merck & Co's insomnia drug suvorexant, issuing CRL

01-07-2013

There was disappointment for US drug giant Merck & Co (NYSE: MRK), which said that it has received a…

Merck & CoNeurologicalNorth AmericaPharmaceuticalRegulationsuvorexant

First nationally-consistent list of hospital medicines takes effect in New Zealand

01-07-2013

People in New Zealand will be able to get the same medicines whichever hospital they visit, as a result…

Asia-PacificHealthcarePharmaceuticalRegulation

Setback for Janssen and Bayer's Xarelto as FDA calls for more info in stent thrombosis setting for ACS patients

01-07-2013

Janssen Research & Development, a unit of US health care giant Johnson & Johnson (NYSE: JNJ) revealed…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Noven's Brisdelle is first non-hormonal treatment for menopausal hot flashes to be approved by FDA

01-07-2013

The US Food and Drug Administration on Friday (June 28) approved Noven Pharmaceuticals' Brisdelle (paroxetine)…

BrisdelleHisamitsu PharmaNorth AmericaNoven PharmaceuticalsparoxetinePharmaceuticalRegulationWomen's Health

Chugai gains Japanese approval for Perjeta and Bonviva

28-06-2013

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) said this morning (June 28) that it has obtained…

Anti-Arthritics/RheumaticsAsia-PacificBonvivaChugai PharmaceuticalOncologyPerjetaPharmaceuticalRegulationRoche

FDA backs Baxter's Rixubis for hemophilia B; Breakthrough status for GSK's drisapersen

28-06-2013

The US Food and Drug Administration yesterday (June 27) approved Baxter International's (NYSE: BAX) Rixubis…

Baxter InternationaldrisapersenGlaxoSmithKlineNorth AmericaPharmaceuticalRare diseasesRegulationRixubis

1030 to 1054 of 3305 results

Back to top